A randomized, double-blind, parallel-group, placebo-controlled study to assess the clinical benefit of SSR411298 as adjunctive treatment for persistent cancer pain

Registry ID

EUCTR2011-002557-56

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

sanofi-aventis

Start date

2011-09-06

Last update

2026-08-16

Conditions

• cancer pain

Summary

• To evaluate the efficacy of SSR411298 200 mg daily compared to placebo as adjunctive treatment for persistent cancer pain, as measured by the change from baseline (baseline = average pain intensity between Visit 1 (Day ­7) and Visit 2 (Day ­1) to end of treatment (end of treatment = average pain intensity during Week 4) in the Numeric Rating Scale (NRS)

Locations

• , , Hungary
• , , Czechia
• , , Italy
• , , Belgium

View on source registry